Powerup Acquisition CORP Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Highbridge Capital Management, LLC has filed a Schedule 13G, reporting beneficial ownership of 78 shares of Aspire Biopharma Holdings, Inc. common stock, representing 0.0% of the class.
Gary Shirinyan has filed a Schedule 13G, reporting beneficial ownership of 99,900 shares, representing 7.7% of Aspire Biopharma Holdings, Inc. common stock.
Lance Friedman has increased his beneficial ownership of Aspire Biopharma Holdings, Inc. common stock to 7.92%, holding 107,323 shares.
Alois Ryan Rubenbauer III has reported beneficial ownership of 65,000 shares, representing 5.0% of Aspire Biopharma Holdings, Inc. common stock.
Highbridge Capital Management, LLC has reported beneficial ownership of 5.2% of Aspire Biopharma Holdings, Inc. common stock, primarily through exercisable warrants.
Ardsley Advisory Partners LP and affiliated entities have filed an amendment to their Schedule 13G, reporting 0% beneficial ownership of Aspire Biopharma Holdings.
Ardsley Advisory Partners and affiliated funds have disclosed a 7.76% beneficial ownership stake in Aspire Biopharma Holdings, Inc. common stock.
SCHEDULE 13G/A: Lance Friedman Amends Stake in Aspire Biopharma Holdings, Inc., Reporting 4.52% Ownership
Lance Friedman has filed an Amendment No. 9 to Schedule 13G, disclosing a 4.52% beneficial ownership stake in Aspire Biopharma Holdings, Inc. as of May 6, 2025.
SCHEDULE 13G/A: Harraden Circle Entities Reduce Stake in Aspire Biopharma Holdings, File Exit Schedule 13G
Harraden Circle Investments and affiliated entities, including Frederick V. Fortmiller, Jr., have significantly reduced their beneficial ownership in Aspire Biopharma Holdings, Inc. to below 5%, triggering an exit filing with the SEC.
Lance Friedman has filed an amended Schedule 13G, reporting beneficial ownership of 7.92% of Aspire Biopharma Holdings, Inc.'s common stock.
Lance Friedman has filed an Amendment No. 7 to Schedule 13G, disclosing a beneficial ownership of 8.25% of Aspire Biopharma Holdings, Inc.'s common stock as of April 21, 2025.
Lance Friedman has disclosed a passive beneficial ownership of 8.28% of Aspire Biopharma Holdings, Inc.'s common stock, totaling 4,051,733 shares, as per a recent Schedule 13G Amendment.
Lance Friedman has filed an amended Schedule 13G, revealing beneficial ownership of 8.55% of Aspire Biopharma Holdings, Inc.'s common stock as of April 4, 2025.
Lance Friedman has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.98% of Aspire Biopharma Holdings, Inc.'s common stock.
Lance Friedman has filed an amended Schedule 13G, reporting a 9.078% beneficial ownership stake in Aspire Biopharma Holdings, Inc. as of March 19, 2025.
Lance Friedman has disclosed a 9.462% passive beneficial ownership stake in Aspire Biopharma Holdings, Inc., totaling 4,609,375 shares of common stock.
Lance Friedman has filed an amended Schedule 13G, revealing a 9.825% passive beneficial ownership stake in Aspire Biopharma Holdings, Inc., totaling 4,804,375 shares.
Lance Friedman has filed a Schedule 13G, revealing a beneficial ownership of 9.98% of Aspire Biopharma Holdings, Inc.'s common stock.